A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
Clinical trial NCT06613360 · RECRUITING
Trial details
- NCT number
- NCT06613360
- Sponsor
- Cullinan Therapeutics Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-21
- Primary completion
- 2026-12-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.